Loading...
•
Dec 31, 2020
Collegium Q4 2020 Earnings Report
Collegium reported a profitable fourth quarter driven by growth in Xtampza ER revenues and the acquisition of the Nucynta franchise.
Key Takeaways
Collegium Pharmaceutical, Inc. reported financial results for Q4 2020, with Xtampza ER revenues increasing by 12% and net income reaching $7.0 million, a significant turnaround from the previous year's net loss. The company's performance was driven by its differentiated pain portfolio and the acquisition of the Nucynta franchise.
Xtampza ER net product revenues increased by 12% to $30.8 million.
Nucynta franchise net product revenues were $45.5 million.
Net income was $7.0 million, or $0.20 earnings per share.
The company secured new exclusive ER oxycodone formulary wins for Xtampza ER.
Forward Guidance
The Company reiterates its full-year 2021 financial guidance, initially provided on January 6, 2021. Collegium is not providing forward-looking guidance for its full-year 2021 U.S. GAAP net income (loss) or a quantitative reconciliation of forward-looking adjusted EBITDA.
Positive Outlook
- Xtampza ER revenues are expected in the range of $155.0 million to $165.0 million.
- Nucynta franchise revenues are expected in the range of $175.0 million to $185.0 million.
- Total operating expenses are expected in the range of $125.0 million to $135.0 million.
- Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $160.0 million to $170.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...